Mukopolysacharidóza I - klinické projevy u 24 dĕtí z České republiky a Slovenska

Ješina, P.; Magner, M.; Poupĕtová, H.; Honzíkova, J.; Dvořáková, L.; Malinová, V.; Hrubá, E.; Hlavatá, A.; Honzík, T.; Veselá, K.; Sedláček, P.; Starý, J.; Zeman, J.
June 2011
Czecho-Slovak Pediatrics / Cesko-Slovenska Pediatrie;Jun2011, Vol. 66 Issue 4, p215
Academic Journal
Mucopolysaccharidosis I (MPS I) is severe metabolic storage disease caused by impaired function of α-L-iduronidase. The aim of this study is to describe clinical symptoms, natural course and to evaluate results of treatment in Czech and Slovak children with MPS I. Methods: Study group consists of 24 children from 23 families. In all children diagnosis of MPS I was confirmed on enzymatic level and in 22 children on molecular level. Results: First symptoms of disease - hepatosplenomegaly, craniofacial dysmorphy, corneal clouding and psychomotor delay - were observed in all patients. The most of them have macrocephaly (11/21) and skeletal changes - dysostosis multiplex (21/23). Cardiomyopathy with valves impairment (16/21), hearing impairment (9/18), joint stiffness (19/22) and carpal tunnel syndrome (7/23) belongs to later symptoms. All children had increased glycosaminoglycans excretion in urine and decreased activity of α-L-iduronidase in isolated leucocytes. Two mutations in gene α-L-iduronidase were prevalent, the mutation p.W402X was found in 9 and the mutation p.Q70X in 7 children. Hematopoietic stem cell transplantation (HSCT) was performed in 7 children, in 5 of them with good clinical result. 6 children with milder form of disease were treated by a long-lasting enzyme replacement therapy (ERT) with good therapeutic effect, but one patient died due to complication after neurosurgery intervention for compression of cervical spinal cord. The most of children without therapy died (7/11). Conclusion: Diagnostic of MPS I in early phases of disease improves prognosis, because correct therapy (HSCT or ERT) can be chosen. Prognosis for children with later diagnosis is very unfavourable. The advance diagnosis is very important also for prenatal diagnostic in affected families.


Related Articles

  • Novel Therapies.  // Current Medical Literature: Lysosomal Storage Disease;2009, Vol. 8 Issue 3, p112 

    The article presents a study which reveals the outcome of haematopoietic stem cell transplantation (HSCT) in six children with mucopolysaccharidosis type IH. During the study, the children were assessed using a developmental before and after the application of HSCT. Researchers conclude that the...

  • Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Boelens, J. J.; Wynn, R. F.; O'Meara, A.; Veys, P.; Bertrand, Y.; Souillet, G.; Wraith, J. E.; Fischer, A.; Cavazzana-Calvo, M.; Sykora, K. W.; Sedlacek, P.; Rovelli, A.; Uiterwaal, C. S. P. M.; Wulffraat, N. // Bone Marrow Transplantation;Aug2007, Vol. 40 Issue 3, p225 

    Hurler's syndrome (HS), the most severe form of mucopolysaccharidosis type-I, causes progressive deterioration of the central nervous system and death in childhood. Allogeneic stem cell transplantation (SCT) before the age of 2 years halts disease progression. Graft failure limits the success of...

  • Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Pal, Abhijit Ricky; Langereis, Eveline J.; Saif, Muhammad A.; Mercer, Jean; Church, Heather J.; Tylee, Karen L.; Wynn, Robert F.; Wijburg, Frits A.; Jones, Simon A.; Bruce, Iain A.; Bigger, Brian W. // Orphanet Journal of Rare Diseases;Jun2015, Vol. 10 Issue 1, p1 

    Background: The lysosomal storage disorder, mucopolysaccharidosis I (MPS I), commonly manifests with upper airway obstruction and sleep disordered breathing (SDB). The success of current therapies, including haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) may...

  • Muskuloskeletální postižení u pacientů s lyzozomálním střádavým onemocnÄ›ním. Májovská, J.; Malinová, V.; Dostálová, G.; Murgašová, L.; Poupětová, H.; Zeman, J.; Magner, M. // Czech Rheumatology / Ceska Revmatologie;2019, Vol. 27 Issue 4, p204 

    Lysosomal storage diseases (LSD) represent a heterogeneous group of > 60 severe hereditary metabolic disorders due to impaired function of one or more lysosomal enzymes or disorders of protein processing and transport across the lysosomal membrane. The diagnosis of LSD is based on clinical...

  • An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life. Kingma, Sandra D. K.; Langereis, Eveline J.; De Klerk, Clasine M.; Zoetekouw, Lida; Wagemans, Tom; IJlst, Lodewijk; Wanders, Ronald J. A.; Wijburg, Frits A.; van Vlies, Naomi // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, p1 

    Introduction: Mucopolysaccharidosis type I (MPS I) is a progressive multisystem lysosomal storage disease caused by deficiency of the enzyme α-L-iduronidase (IDUA). Patients present with a continuous spectrum of disease severity, and the most severely affected patients (Hurler phenotype; MPS...

  • Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice. McCarty, Douglas M.; DiRosario, Julianne; Gulaid, Kadra; Killedar, Smruti; Oosterhof, Arie; Van Kuppevelt, Toin H.; Martin, Paul T.; Haiyan Fu // Metabolic Brain Disease;Mar2011, Vol. 26 Issue 1, p9 

    The primary pathology in mucopolysaccharidosis (MPS) IIIB is lysosomal storage of heparan sulfate (HS) glycosaminoglycans, leading to complex neuropathology and dysfunction, for which the detailed mechanisms remain unclear. Using antibodies that recognize specific HS glycoforms, we demonstrate...

  • Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Lawrence, Roger; Brown, Jillian R; Al-Mafraji, Kanar; Lamanna, William C; Beitel, James R; Boons, Geert-Jan; Esko, Jeffrey D; Crawford, Brett E // Nature Chemical Biology;Feb2012, Vol. 8 Issue 2, p197 

    A considerable need exists for improved biomarkers for differential diagnosis, prognosis and monitoring of therapeutic interventions for mucopolysaccharidoses (MPS), inherited metabolic disorders that involve lysosomal storage of glycosaminoglycans. Here we report a simple, reliable method based...

  • Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Dziedzic, Dariusz; Węgrzyn, Grzegorz; Jakóbkiewicz-Banecka, Joanna // European Journal of Human Genetics;Feb2010, Vol. 18 Issue 2, p200 

    Mucopolysaccharidoses (MPS) are severe inherited metabolic disorders from the group of lysosomal storage diseases. They are caused by deficiency in the activity of enzymes involved in the degradation of glycosaminoglycans (GAGs) and resultant accumulation of these compounds in the cells of...

  • Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Anson, Donald S.; McIntyre, Chantelle; Thomas, Belinda; Koldej, Rachel; Ranieri, Enzo; Roberts, Ainslie; Clements, Peter R.; Dunning, Kylie; Byers, Sharon // Genetic Vaccines & Therapy;2007, Vol. 5, p1 

    Background: Mucopolysaccharidosis type IIIA (MPS IIIA) is the most common of the mucopolysaccharidoses. The disease is caused by a deficiency of the lysosomal enzyme sulphamidase and results in the storage of the glycosaminoglycan (GAG), heparan sulphate. MPS IIIA is characterised by widespread...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics